Partnerships
The World Health Organization predicts a sharp rise in breast cancer cases. By 2050, the number of cases is expected to increase by nearly 60%, and over a million women will die from it. But it doesn’t have to be that way.
At AILIS, we have created a solution that can save their lives.
Join The Global Healthcare Revolution
The AILIS system is the result of the effort of over 100 scientists, doctors, engineers, and programmers from top scientific institutions and research centers.
The development of the AILIS early breast cancer detection system took 8 years.
The project received over PLN 6.5 million in funding from the EU Funds.
The AILIS system is currently undergoing clinical evaluation.
As we prepare for medical certification, we are seeking partners who would like to work with us to bring the AILIS system to global markets.
Why The World Needs AILIS
We have addressed the key challenges in breast cancer:
- The sharp rise in breast cancer cases (nearly 60% by 2050 according to the WHO).
- The late diagnosis (stage III and IV) and its high mortality rate (29%).
- The shortage of medical personnel and radiologists.
- The low participation rate in breast cancer screening programs (54.5% – EU average).
Getting Ahead of the Disease
Our vision is a world where breast cancer is no longer a life-threatening disease.
By bringing the most advanced, AI-powered early detection system to women,
we are making frequent, comfortable, and accessible breast exams a reality.
When detected early, breast cancer has a nearly 100% survival rate. With our non-contact,
painless, and non-invasive technology, women can now get screened regularly outside
of medical facilities. This revolutionary approach is within reach, and we’re committed
to making it a new standard of healthcare.
Michał Matuszewski
CEO AILIS
High Scalability Thanks
To Advanced AI Algorithms
Standard breast cancer detection methods typically require significant human labor and financial investment. In contrast, AILIS utilizes advanced AI algorithms, a high level of automation and standardization, minimizing the need for medical staff. The core innovations that enable AILIS’s scalability are its AI technology, highly automated and standardized procedures, and the ability to operate with fewer medical personnel compared to conventional approaches. That allows for rapid expansion into new markets and regions.
Designed Together With Women
The AILIS breast examination was designed together with women
to break down barriers related to breast cancer screenings.
We have examined nearly 1000 women, whose feedback confirms
that AILIS is a well-planned experience.
AILIS, taking into account the needs of women, encourages them
to get their breasts examined and to regularly monitor
the health of their breasts.
Pioneering AI-Powered Early Breast Cancer Detection
AILIS is at the forefront of medical innovation, utilizing advanced
AI solutions to revolutionize early breast cancer detection. Ranked
3rd among the best Polish firms developing cutting-edge AI technologies
in the prestigious Forbes “Creators of a Better Future” list, AILIS
has garnered global attention for its unique approach.
The increasing demand for remote healthcare access, combined with the growing
interest in women’s health and lifestyle medicine, creates an ideal environment
for AILIS’ groundbreaking technology, based on automatization and telemedicine,
that has a chance to revolutionize early breast cancer detection.
World-class Design
„Winning the prestigious Red Dot Award we have proven that small and agile companies can effectively compete with the medical industry giants. By utilizing advanced AI algorithms, startups are questioning the status quo, and introducing groundbreaking innovations in the health sector. We have shown that Poland can create innovative technologies that set new trends and cater to the needs of the modern world.”
Michał Matuszewski, CEO of AILIS
